[166] The HER2 mAb pertuzumab represents a new class of drugs called dimerization inhibitors; these have the potential to block signaling by other HER family receptors, as well as inhibiting ...

FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free ...

the company's innovative anti-HER2 monoclonal antibody (mAb) for the treatment of gastric cancer. According to the U.S. FDA, the drug or biological product receives an ODD will be eligible for ...

SHANGHAI, March 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the ...

the company's innovative anti-HER2 monoclonal antibody (mAb) for the treatment of gastric cancer. Receiving an Orphan Drug Designation for HLX22 recognizes its potential to treat patients with ...

On March 19, 2025, Shanghai Henlius Biotech announced that the FDA has granted Orphan Drug Designation for HLX22, an anti-HER2 monoclonal antibody, for the treatment of gastric cancer. HLX22 binds ...